🇺🇸 FDA
Pipeline program

ORMD-0801 QD

ORA-D-N01B

Phase 2 small_molecule completed

Quick answer

ORMD-0801 QD for Nonalcoholic Steatohepatitis (NASH) is a Phase 2 program (small_molecule) at ORAMED PHARMACEUTICALS INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
ORAMED PHARMACEUTICALS INC.
Indication
Nonalcoholic Steatohepatitis (NASH)
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials